Trial reportScientific reports2026
Exploratory crossover field study indicates efficacy and feasibility of light therapy glasses to mitigate fatigue in multiple sclerosis.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatigue is highly prevalent, clinically significant, and persistent in multiple sclerosis (MS), highlighting the need for effective countermeasures. To evaluate the feasibility and efficacy of blue-enriched bright light (BL) therapy glasses in reducing MS-related fatigue, this single-blind, randomized, active-controlled crossover study included 20 patients with MS with significant fatigue (Fatigue Severity Scale [FSS] total score > 36). Participants used blue light (BL) glasses or dim red light (DRL) glasses for 20 min daily after waking. Each intervention lasted 1 week with a 6-day washout between conditions. Fatigue, measured using the FSS four times per intervention week, was the main exploratory outcome measure. Further, the acute overall effects of both interventions were assessed using a Visual Analogue Scale for Fatigue (VAS_F) immediately before and after each intervention and at 13:00. Quality of life (Multicultural Quality of Life Index) was rated four times per week. Feasibility was evaluated using self-reported comfort, side effects, and sleep quality. Both interventions significantly decreased total FSS scores on the sixth and seventh intervention days (follow-up), with BL inducing clinically significant reductions on the sixth day. Both interventions significantly reduced VAS_F ratings immediately after the intervention and at 13:00, with BL showing significantly more reduction. No effects on quality of life were observed. Patients reported greater comfort, improved well-being, and reduced fatigue with the BL glasses. Side effects were low and subjective sleep quality was unaffected. Despite its small sample size, the present exploratory study provides initial evidence for light therapy glasses as a feasible, immediately effective intervention for MS-related fatigue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.